ATE551050T1 - Stabilisierte zusammensetzungen für rekombinant hergestellten faktor viii - Google Patents

Stabilisierte zusammensetzungen für rekombinant hergestellten faktor viii

Info

Publication number
ATE551050T1
ATE551050T1 AT09782562T AT09782562T ATE551050T1 AT E551050 T1 ATE551050 T1 AT E551050T1 AT 09782562 T AT09782562 T AT 09782562T AT 09782562 T AT09782562 T AT 09782562T AT E551050 T1 ATE551050 T1 AT E551050T1
Authority
AT
Austria
Prior art keywords
factor viii
recombinantly produced
stabilized compositions
produced factor
stabilized
Prior art date
Application number
AT09782562T
Other languages
English (en)
Inventor
Brita Rippner
Josefin Oesterberg
Ulrika Nilsson
Elsa Ivarsson
Irene Agerkvist
Original Assignee
Octapharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Octapharma Ag filed Critical Octapharma Ag
Application granted granted Critical
Publication of ATE551050T1 publication Critical patent/ATE551050T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
AT09782562T 2008-09-03 2009-09-03 Stabilisierte zusammensetzungen für rekombinant hergestellten faktor viii ATE551050T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13640208P 2008-09-03 2008-09-03
EP08163554 2008-09-03
PCT/EP2009/061402 WO2010026186A1 (en) 2008-09-03 2009-09-03 New protecting compositions for recombinantly produced factor viii

Publications (1)

Publication Number Publication Date
ATE551050T1 true ATE551050T1 (de) 2012-04-15

Family

ID=39791048

Family Applications (1)

Application Number Title Priority Date Filing Date
AT09782562T ATE551050T1 (de) 2008-09-03 2009-09-03 Stabilisierte zusammensetzungen für rekombinant hergestellten faktor viii

Country Status (19)

Country Link
US (4) US20110178019A1 (de)
EP (1) EP2337580B1 (de)
JP (2) JP5960990B2 (de)
KR (3) KR101691443B1 (de)
CN (3) CN107049964B (de)
AT (1) ATE551050T1 (de)
AU (1) AU2009289212B2 (de)
BR (1) BRPI0918589B1 (de)
CA (1) CA2735376C (de)
DK (1) DK2337580T3 (de)
ES (1) ES2382443T3 (de)
IL (1) IL211083A (de)
MX (1) MX2011002316A (de)
PL (1) PL2337580T3 (de)
PT (1) PT2337580E (de)
RU (1) RU2510279C3 (de)
SI (1) SI2337580T1 (de)
WO (1) WO2010026186A1 (de)
ZA (1) ZA201101605B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE365052T1 (de) 1999-02-22 2007-07-15 Univ Connecticut Neue albuminfreie faktor viii formulierungen
NZ593190A (en) 2008-11-07 2013-01-25 Baxter Int Factor viii formulations
CN102232932B (zh) * 2010-04-27 2013-06-05 重庆莱美药业股份有限公司 果胶-阿霉素轭合物的冻干制剂及制备方法
KR102321339B1 (ko) * 2013-07-18 2021-11-02 맨카인드 코포레이션 열-안정성 건조 분말 약제학적 조성물 및 방법
JP6778111B2 (ja) 2014-01-20 2020-10-28 オクタファルマ・アーゲー ＦＶＩＩＩ：Ｃ／ＦＶＩＩＩ：Ａｇの改良された比を有する第ＶＩＩＩ因子を製造するための方法
ES2788870T3 (es) * 2014-08-04 2020-10-23 Csl Ltd Formulación de factor VIII
EA036091B1 (ru) 2014-08-20 2020-09-25 Портола Фармасьютикалз, Инк. ВОДНЫЕ СОСТАВЫ АНТИДОТОВ ФАКТОРА Xa (fXa) ДЛЯ ПРЕДУПРЕЖДЕНИЯ ИЛИ УМЕНЬШЕНИЯ КРОВОТЕЧЕНИЯ И ИХ ПРИМЕНЕНИЕ
WO2017147522A1 (en) * 2016-02-24 2017-08-31 Portola Pharmaceuticals, Inc. Lyophilized formulations for factor xa antidote
WO2017180594A1 (en) * 2016-04-13 2017-10-19 Medimmune, Llc Use of amino acids as stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents
EP4013389A1 (de) 2019-08-16 2022-06-22 Octapharma AG Stabilisierender puffer für faktor viii und vwf
CN116479088A (zh) * 2022-11-15 2023-07-25 江苏默乐生物科技股份有限公司 一种生物试剂冻干保存的试剂组合、试剂盒、方法及应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605884A (en) * 1987-10-29 1997-02-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Factor VIII formulations in high ionic strength media
US4877608A (en) * 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
DE4001451A1 (de) * 1990-01-19 1991-08-01 Octapharma Ag Stabile injizierbare loesungen von faktor viii und faktor ix
DE4111393A1 (de) * 1991-04-09 1992-10-15 Behringwerke Ag Stabilisierte faktor viii-praeparationen
US5288853A (en) * 1992-04-30 1994-02-22 Alpha Therapeutic Corporation Factor viii purification process
CA2124690C (en) * 1992-10-02 2007-09-11 Thomas Osterberg Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer
SE9301581D0 (sv) * 1993-05-07 1993-05-07 Kabi Pharmacia Ab Protein formulation
SE9403915D0 (sv) * 1994-11-14 1994-11-14 Annelie Almstedt Process A
US5763401A (en) * 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
US6005007A (en) * 1997-07-18 1999-12-21 Farmer; Luc J. Retinoids, methods for their production and use
US6358703B1 (en) * 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
ATE365052T1 (de) * 1999-02-22 2007-07-15 Univ Connecticut Neue albuminfreie faktor viii formulierungen
AU6558400A (en) * 1999-08-17 2001-03-13 Novo Nordisk A/S Stabilisation of freeze-dried cake
SE0004086D0 (sv) * 2000-11-08 2000-11-08 Pharmacia Ab Preparation process
GB0207092D0 (en) * 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
AU2004216298B2 (en) * 2003-02-28 2009-04-23 Chugai Seiyaku Kabushiki Kaisha Stabilized protein-containing formulations
KR100624013B1 (ko) * 2004-06-25 2006-09-19 주식회사 녹십자홀딩스 동결건조된 알부민 비함유 재조합 사람 혈액응고 제 8인자 제제
US20080227691A1 (en) * 2005-04-01 2008-09-18 Novo Nordisk Health Care Ag Blood Coagulation FVIII Analogues
CN101415445A (zh) * 2006-03-31 2009-04-22 巴克斯特国际公司 聚乙二醇化的因子ⅷ
WO2008073620A2 (en) * 2006-11-02 2008-06-19 Neose Technologies, Inc. Manufacturing process for the production of polypeptides expressed in insect cell-lines
WO2009006301A2 (en) * 2007-06-29 2009-01-08 Battelle Memorial Institute Protein stabilization
BRPI0914695B1 (pt) * 2008-06-24 2022-04-19 Octapharma Ag Processo de purificação ou enriquecimento de fator fviii de coagulação
MX2011003074A (es) * 2008-09-24 2011-04-19 Stabilitech Ltd Metodo para conservar polipeptidos utilizando un azucar y polietilenimina.

Also Published As

Publication number Publication date
CN107050437A (zh) 2017-08-18
CN102143759A (zh) 2011-08-03
KR101691070B1 (ko) 2016-12-29
CN107049964B (zh) 2020-06-02
DK2337580T3 (da) 2012-07-09
IL211083A0 (en) 2011-07-31
JP5960990B2 (ja) 2016-08-02
WO2010026186A1 (en) 2010-03-11
JP6010155B2 (ja) 2016-10-19
US20110178019A1 (en) 2011-07-21
BRPI0918589B1 (pt) 2021-07-13
KR20110073434A (ko) 2011-06-29
SI2337580T1 (sl) 2012-06-29
KR20160093743A (ko) 2016-08-08
MX2011002316A (es) 2011-05-10
US20170189494A1 (en) 2017-07-06
US20190358301A1 (en) 2019-11-28
JP2012502004A (ja) 2012-01-26
KR101691443B1 (ko) 2016-12-30
EP2337580B1 (de) 2012-03-28
US20150190478A1 (en) 2015-07-09
CA2735376A1 (en) 2010-03-11
AU2009289212B2 (en) 2015-02-12
RU2011112787A (ru) 2012-10-10
ES2382443T3 (es) 2012-06-08
EP2337580A1 (de) 2011-06-29
PT2337580E (pt) 2012-05-28
PL2337580T3 (pl) 2012-08-31
ZA201101605B (en) 2011-10-26
BRPI0918589A2 (pt) 2017-04-11
CN107049964A (zh) 2017-08-18
IL211083A (en) 2016-09-29
CA2735376C (en) 2016-11-29
RU2510279C2 (ru) 2014-03-27
RU2510279C3 (ru) 2017-04-17
KR20160114194A (ko) 2016-10-04
AU2009289212A1 (en) 2010-03-11
JP2015129158A (ja) 2015-07-16

Similar Documents

Publication Publication Date Title
ATE551050T1 (de) Stabilisierte zusammensetzungen für rekombinant hergestellten faktor viii
JOP20180103B1 (ar) التركيب الصيدلاني للكاربيتوسين
ATE542552T1 (de) Injizierbarer hohlraumfüller für weichgewebevergrösserung
TR201902435T4 (tr) DGAT1 inhibitör içeren farmasötik bileşimler.
PA8848201A1 (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes
MX2010002902A (es) Pirimidinas anti-infecciosas y usos de las mismas.
SV2008003045A (es) Aminotetrahidropiranos como inhibidores de dipertidil, peptidasa-iv para el tratamiento o prevencion de diabetes
UA116809C2 (uk) Застосування агрохімічних сумішей для збільшення життєздатності рослини
BR112013028816A2 (pt) "análogos de compstatina, composição que os compreende e uso dos mesmos".
TN2012000010A1 (en) Long acting insulin composition
IN2012DN01330A (de)
CO6400206A2 (es) Composición espumante para alta temperatura y salinidad
SG191069A1 (en) Cyclosporine analogue molecules modified at amino acid 1 and 3
EA201270216A1 (ru) Фармацевтический состав
EA201290374A1 (ru) Аэрозольная композиция для copd
MY166449A (en) Pharmaceutical composition of rosuvastatin calcium
AR081165A1 (es) Composicion dental
MA32215B1 (fr) Cristal de compose de benzimidazole
MX2013000793A (es) Composicion que contiene galacto-oligosacarido y un metodo para producirla.
SG158091A1 (en) Imidazoazepinone compounds
DOP2010000329A (es) Inhibidores de la renina
MX2009008028A (es) Agentes antiparasitarios.
BR112012024329A2 (pt) composição endoparasiticidas
BR112012020674A2 (pt) artigo depilatório aquoso e flexível
FR2908780B1 (fr) Composition deneigeante antiderapante